DALENOR HALLS: Open Payments
NPI 1538183413 · MESA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$860 in 41 payments from 18 companies in 2025. Trend: 2023 $1,041 · 2024 $965 · 2025 $860
Food & beverage: $860
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 5 | $103 |
| Dexcom, Inc. | 4 | $97 |
| Novo Nordisk Inc | 4 | $73 |
| Novartis Pharmaceuticals Corporation | 3 | $69 |
| GlaxoSmithKline, LLC. | 3 | $65 |
| SANOFI-AVENTIS U.S. LLC | 3 | $54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 2 | $51 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $38 |
Products named: Dexcom G6 Transmitter, LEQVIO, OTEZLA, TRELEGY ELLIPTA, TZIELD, Ozempic, ZORYVE, Kerendia.
Industry payments across AZ — which companies pay providers there.
